The B. Braun Streamline Bloodline Set FDA alert, posted on 27 October 2026, covers three manufacturing lots of one hemodialysis blood tubing set. The US Food and Drug Administration published an early alert after B. Braun told customers that a required solvent step was skipped during assembly, which could leave the dialyzer connector badly bonded. The agency says it is still reviewing the information. This article sets out exactly which product and lots are named, what the risks are, what B. Braun has told customers and what remains unknown, without suggesting that other B. Braun dialysis products are affected.
Key takeaways from the B. Braun Streamline Bloodline Set FDA alert
- The product is the Streamline Bloodline Set for Dialog+, model SL-2010M2096, described by the FDA as a blood tubing set indicated for hemodialysis.
- The affected lots are A2600099, A2600128 and A2600136; the alert lists no other model or lot.
- B. Braun said a required solvent application step during assembly was not performed, so the dialyzer connector may not have bonded properly.
- As of 10 October 2026, the FDA page says B. Braun had reported no serious injuries or deaths linked to the issue.
- On 20 October 2026, B. Braun sent customers a letter recommending that affected bloodlines be removed from use or sale.
What the FDA early alert says: the B. Braun Streamline Bloodline Set FDA alert in detail
An early alert is the FDA’s way of telling the public about a potentially high-risk device problem while its review is still under way. It is not a formal recall classification, and the page says the agency is currently reviewing information about the issue. The page gives the model number SL-2010M2096 and two unique device identifiers, 04046964367786 and 04046964367779. It does not state how many units were distributed or when. The original notice is on the FDA website.
Why the connector matters in the B. Braun Streamline Bloodline Set FDA alert
A bloodline set is the tubing that carries a patient’s blood from the body to the dialyzer, the filter that cleans it, and back again. The connector that joins the tubing to the dialyzer must hold under pressure for hours. According to the FDA page, if the connector is poorly bonded it may detach or leak during priming or treatment. Possible consequences listed include blood loss, clotting, blockage of the circuit and air entering the blood circuit. Blood loss may require stopping treatment, replacing the bloodline, clinical assessment or hospital care, and severe loss could be life-threatening. The page also notes that air passing the machine’s air detection is rare but could cause an air embolism and death.
What B. Braun told customers after the B. Braun Streamline Bloodline Set FDA alert
Customers received a letter dated 20 October 2026. Per the FDA summary, they were asked to inform all users and other concerned people, forward the notice if they are distributors, identify affected inventory, stop using it, quarantine it and return it to the manufacturer. US customers can contact B. Braun at recalls@bbraunusa.com or (610) 849-1197. Adverse events or product quality problems can be reported to the FDA’s MedWatch programme.
What dialysis units should check after the B. Braun Streamline Bloodline Set FDA alert
Based on the FDA summary, units should look for model SL-2010M2096 in stock and compare lot numbers with the three listed. Sets from other lots of the same model are not named in this alert. Any matching sets should be quarantined and the manufacturer contacted. Clinicians with questions about individual patients should follow their own facility protocols, since this article cannot give clinical instructions.
An earlier, separate FDA notice on the same model
The same model, SL-2010M2096, was the subject of an earlier FDA notice about a different set of lots, where B. Braun said manufacturing damage to patient connectors could allow micro-air bubbles or leakage. That notice relates to lots in the A25 series and a different cause, and its page carries inconsistent dates, so we do not treat it as part of the current alert. Readers should not confuse the two. See the earlier FDA notice for that issue.
Market context from Acumen Research and Consulting
Dialysis is a large and growing field. Acumen Research and Consulting’s Dialysis Market report values the global market at USD 107.3 billion in 2024 and projects USD 184.4 billion by 2033, a CAGR of 6.3% from 2025 to 2033. It says hemodialysis held 57% of the market in 2024, in-center dialysis accounted for 68% of end use and Asia Pacific is the fastest-growing region at over 7% a year. The page carries a last-updated date of 2019 that conflicts with its 2024 base year, so treat the figures as estimates. They describe the whole market and say nothing about this alert. Related coverage is in our Medical Device section.
Timeline of the B. Braun Streamline Bloodline Set FDA alert
- 10 October 2026: reference date for the statement that no serious injuries or deaths had been reported to B. Braun.
- 20 October 2026: B. Braun sends its customer letter.
- 27 October 2026: the FDA publishes the early alert.
General background: how early alerts work
The FDA’s early alert pilot allows the agency to share information about a possible high-risk problem before the full recall classification is done. Information may change as the review continues, and the alert may later be updated or reclassified.
Our analysis of the B. Braun Streamline Bloodline Set FDA alert
In our assessment, the B. Braun Streamline Bloodline Set FDA alert is narrow but serious in kind. It names one model and three lots, and the absence of reported serious injuries as of 10 October is reassuring, but the hazards described are the type that matter in dialysis, where treatment lasts hours and patients are often vulnerable. The practical steps are simple: identify, quarantine and return. We do not know how many sets are in the field.
What is not disclosed in the B. Braun Streamline Bloodline Set FDA alert
- The number of units and the distribution dates.
- Whether any adverse events have been reported since 10 October.
- The FDA’s final recall classification.
- Any replacement supply timeline from B. Braun.
Risks and caveats
The alert may be updated. We have relied on the FDA page and have not independently verified the manufacturer’s statements. This article is news reporting and not medical or regulatory advice.
What to watch next in the B. Braun Streamline Bloodline Set FDA alert
- Updates to the FDA alert page.
- A formal recall classification.
- Any further B. Braun customer communication.
FAQ
Are all B. Braun dialysis products affected?
No. The alert names only model SL-2010M2096 and lots A2600099, A2600128 and A2600136.
Has anyone been seriously harmed?
As of 10 October 2026, B. Braun reported no serious injuries or deaths associated with the issue.
Is this a formal FDA recall?
It is an early alert, and the FDA says it is still reviewing the information.
How we reported this: we relied on the FDA’s alert page and the Acumen Research and Consulting report cited above. Last updated 28 October 2026. This is news reporting and not advice.